Literature DB >> 26558654

From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology.

Helen McShane1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26558654      PMCID： PMC4962746          DOI： 10.1080/21645515.2015.1100912

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  9 in total

1.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Authors:  Clare R Sander; Ansar A Pathan; Natalie E R Beveridge; Ian Poulton; Angela Minassian; Nicola Alder; Johan Van Wijgerden; Adrian V S Hill; Fergus V Gleeson; Robert J O Davies; Geoffrey Pasvol; Helen McShane
Journal:  Am J Respir Crit Care Med       Date:  2009-01-16       Impact factor: 21.405

2.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

3.  Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Authors:  Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

4.  Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Authors:  Martin O C Ota; Aderonke A Odutola; Patrick K Owiafe; Simon Donkor; Olumuyiwa A Owolabi; Nathaniel J Brittain; Nicola Williams; Sarah Rowland-Jones; Adrian V S Hill; Richard A Adegbola; Helen McShane
Journal:  Sci Transl Med       Date:  2011-06-22       Impact factor: 17.956

5.  A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults.

Authors:  Angela M Minassian; Rosalind Rowland; Natalie E R Beveridge; Ian D Poulton; Iman Satti; Stephanie Harris; Hazel Poyntz; Matthew Hamill; Kristin Griffiths; Clare R Sander; David R Ambrozak; David A Price; Brenna J Hill; Joseph P Casazza; Daniel C Douek; Richard A Koup; Mario Roederer; Alan Winston; Jonathan Ross; Jackie Sherrard; Guy Rooney; Nicola Williams; Alison M Lawrie; Helen A Fletcher; Ansar A Pathan; Helen McShane
Journal:  BMJ Open       Date:  2011-11-14       Impact factor: 2.692

6.  Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

Authors:  Iman Satti; Joel Meyer; Stephanie A Harris; Zita-Rose Manjaly Thomas; Kristin Griffiths; Richard D Antrobus; Rosalind Rowland; Raquel Lopez Ramon; Mary Smith; Sharon Sheehan; Henry Bettinson; Helen McShane
Journal:  Lancet Infect Dis       Date:  2014-08-20       Impact factor: 25.071

7.  Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

Authors:  Tandakha N Dieye; Birahim P Ndiaye; Alle B Dieng; Marema Fall; Nathaniel Brittain; Nathaniel Britain; Samantha Vermaak; Makhtar Camara; Halimatou Diop-Ndiaye; Ndeye Fatou Ngom-Gueye; Papa A Diaw; Coumba Toure-Kane; Papa S Sow; Souleymane Mboup; Helen McShane
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

8.  Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

Authors:  Birahim Pierre Ndiaye; Friedrich Thienemann; Martin Ota; Bernard S Landry; Makhtar Camara; Siry Dièye; Tandakha Ndiaye Dieye; Hanif Esmail; Rene Goliath; Kris Huygen; Vanessa January; Ibrahima Ndiaye; Tolu Oni; Michael Raine; Marta Romano; Iman Satti; Sharon Sutton; Aminata Thiam; Katalin A Wilkinson; Souleymane Mboup; Robert J Wilkinson; Helen McShane
Journal:  Lancet Respir Med       Date:  2015-02-26       Impact factor: 102.642

9.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.